摘要目的 探讨窄谱中波紫外线(NB-UVB)对寻常性银屑病患者血清中白细胞介素(IL)6和17的影响.方法 40例银屑病患者用NB-UVB照射治疗,每周3次,共治疗6周,分别于光疗前、光疗9次和光疗18次后,测定患者治疗前后血清IL-6和IL-17的水平,并以40例健康人作对照.结果 患者NB-UVB治疗前PASI评分15.68±2.86,光疗9次为10.58±1.36,光疗18次后为3.08±1.37,治疗前后评分对照,差异有统计学意义(P＜0.01).银屑病患者NB-UVB照射治疗前后,IL-6水平分别为(61.82±15.61)pg/L和(20.43±9.78)pg/L,差异有统计学意义(P＜0.05).IL-17水平分别为(41.56±10.34) pg/L和(26.32±7.24)pg/L,差异有统计学意义(P＜0.05).健康人血清IL-6和IL-17水平分别为(1.50±1.82) pg/L和(13.47±2.15)pg/L,健康人之间差异无统计学意义(P＞0.05).40例银屑病患者中,治愈20例,显效15例,有效率为87.5％.结论 NB-UVB照射可提高银屑病的疗效,并降低外周血IL-6、IL-17的水平.

abstractsObjective To evaluate the effect of narrow-band ultraviolet B (NB-UVB) on serum levels of interleukin (IL)-6 and IL-17 in patients with psoriasis vulgaris.Methods Totally, 40 patients with psoriasis vulgaris and 40 healthy volunteers were enrolled into this study.All the patients were treated with NB-UVB radiation thrice a week for 6 consecutive weeks.Venous blood samples were obtained from these healthy controls and patients before start of treatment, and after 9 and 18 sessions of radiation.Enzyme-linked immunosorbent assay (ELISA) was conducted to detect the serum levels of IL-6 and IL-17 in these subjects.Results The psoriasis area and severity index (PASI) score was 15.68 ± 2.86 before the initial radiation, 10.58 ± 1.36 after 9 sessions of radiation, and 3.08 ± 1.37 after 18 sessions of radiation, and there were significant differences between the PASI score before the initial radiation and that after 18 sessions of radiation (P ＜ 0.01).The serum levels of IL-6 and IL-17 in the patients before start of treatment were (61.82 ± 15.61) pg/L and (41.56 ± 10.34) pg/L respectively, significantly higher than those in them after 18 sessions of NB-UVB radiation ([20.43 ± 9.78] pg/L and [26.32 ± 7.24]) pg/L, respectively, both P ＜ 0.05), and those in healthy controls ([1.50 ± 1.82] pg/L and [13.47 ± 2.15]) pg/L, respectively, both P ＜ 0.05).Among the 40 patients with psoriasis vulgaris, 20 were cured and 15 showed marked response, with the response rate being 87.5％.Conclusion NB-UVB phototherapy can increase therapeutic outcomes in patients with psoriasis vulgaris, and decrease the levels of IL-6 and IL-17 in peripheral blood.